Sharon X. Wen

Array ( [id] => 19273247 [patent_doc_number] => 12023354 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-02 [patent_title] => Targeting B cell activating factor receptor (BAFF-R) using ligand-based chimeric antigen receptor (CAR)-T cells [patent_app_type] => utility [patent_app_number] => 16/888989 [patent_app_country] => US [patent_app_date] => 2020-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 10 [patent_no_of_words] => 7659 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16888989 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19410607 [patent_doc_number] => 12076400 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-03 [patent_title] => Methods of using a bispecific antigen-binding construct targeting HER2 in combination with CDK4/6 inhibitors for the treatment of breast cancer [patent_app_type] => utility [patent_app_number] => 16/887460 [patent_app_country] => US [patent_app_date] => 2020-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 39238 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 176 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16887460 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16727902 [patent_doc_number] => 20210095049 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-01 [patent_title] => METHOD OF INHIBITING ECTOPIC CALCIFICATION [patent_app_type] => utility [patent_app_number] => 16/876350 [patent_app_country] => US [patent_app_date] => 2020-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3217 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16876350 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16253532 [patent_doc_number] => 20200262906 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-20 [patent_title] => ANTIBODIES AGAINST PHOSPHORYLCHOLINE IN COMBINATION THERAPY WITH BIOLOGIC AGENTS [patent_app_type] => utility [patent_app_number] => 16/868323 [patent_app_country] => US [patent_app_date] => 2020-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13341 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16868323 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18666307 [patent_doc_number] => 11773185 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-03 [patent_title] => Anti-BACE1 antibodies and methods of use thereof [patent_app_type] => utility [patent_app_number] => 16/867942 [patent_app_country] => US [patent_app_date] => 2020-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 13 [patent_no_of_words] => 96637 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16867942 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17214575 [patent_doc_number] => 20210347912 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => YKL-40 ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/867050 [patent_app_country] => US [patent_app_date] => 2020-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9413 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 150 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16867050 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16598112 [patent_doc_number] => 20210024643 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-28 [patent_title] => METHOD FOR TREATING JOINT DAMAGE [patent_app_type] => utility [patent_app_number] => 16/866757 [patent_app_country] => US [patent_app_date] => 2020-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51571 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16866757 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17702929 [patent_doc_number] => 20220202935 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => Immunogen for Preventing or Treating Familial Frontotemporal Dementia (FTD) and/or Amyotrophic Lateral Sclerosis (ALS) [patent_app_type] => utility [patent_app_number] => 17/606851 [patent_app_country] => US [patent_app_date] => 2020-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21206 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17606851 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16362434 [patent_doc_number] => 20200319185 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-08 [patent_title] => PCSK9 ANTIBODY, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/855202 [patent_app_country] => US [patent_app_date] => 2020-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7783 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16855202 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16268638 [patent_doc_number] => 20200270125 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => NUCLEIC ACIDS ENCODING ANTIBODIES SPECIFICALLY BINDING TO MASP-3 [patent_app_type] => utility [patent_app_number] => 16/837600 [patent_app_country] => US [patent_app_date] => 2020-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 103562 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16837600 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16376375 [patent_doc_number] => 20200325217 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-15 [patent_title] => SULFONATED SCLEROSTIN, ANTIBODIES, EPITOPES AND METHODS FOR IDENTIFICATION AND USE THEREFOR [patent_app_type] => utility [patent_app_number] => 16/830330 [patent_app_country] => US [patent_app_date] => 2020-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9885 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16830330 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16189393 [patent_doc_number] => 20200230242 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-23 [patent_title] => METHODS OF USING CTLA4Ig SUBCUTANEOUS FORMULATIONS [patent_app_type] => utility [patent_app_number] => 16/828867 [patent_app_country] => US [patent_app_date] => 2020-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23642 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -82 [patent_words_short_claim] => 156 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16828867 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16483989 [patent_doc_number] => 20200377590 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-03 [patent_title] => VH-VL INTERDOMAIN ANGLE BASED ANTIBODY HUMANIZATION [patent_app_type] => utility [patent_app_number] => 16/820094 [patent_app_country] => US [patent_app_date] => 2020-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29310 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16820094 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17727780 [patent_doc_number] => 11384155 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-07-12 [patent_title] => Antigen binding molecules specific for an anti-CD19 scFv [patent_app_type] => utility [patent_app_number] => 16/814661 [patent_app_country] => US [patent_app_date] => 2020-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 46126 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 113 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16814661 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19904177 [patent_doc_number] => 12281173 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-22 [patent_title] => Methods for treating patients with hyperlipidemia by administering a PCSK9 inhibitor in combination with an ANGPTL3 inhibitor [patent_app_type] => utility [patent_app_number] => 16/808058 [patent_app_country] => US [patent_app_date] => 2020-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 8352 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 250 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16808058 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16328444 [patent_doc_number] => 20200299410 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-24 [patent_title] => CRYSTALLINE ANTIBODY FORMULATIONS [patent_app_type] => utility [patent_app_number] => 16/799601 [patent_app_country] => US [patent_app_date] => 2020-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23315 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 7 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16799601 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16238284 [patent_doc_number] => 20200255518 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-13 [patent_title] => ANTIBODIES WITH ENHANCED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY ACTIVITY, METHODS OF THEIR PRODUCTION AND USE [patent_app_type] => utility [patent_app_number] => 16/798047 [patent_app_country] => US [patent_app_date] => 2020-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27489 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16798047 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16236824 [patent_doc_number] => 20200254058 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-13 [patent_title] => THERAPEUTIC TREM-1 PEPTIDES [patent_app_type] => utility [patent_app_number] => 16/794037 [patent_app_country] => US [patent_app_date] => 2020-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21014 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16794037 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16541017 [patent_doc_number] => 20200407430 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-31 [patent_title] => ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE beta (HPTPbeta) AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/784970 [patent_app_country] => US [patent_app_date] => 2020-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12795 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16784970 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17561687 [patent_doc_number] => 20220125836 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-28 [patent_title] => TREATMENT INVOLVING CAR-ENGINEERED T CELLS AND CYTOKINES [patent_app_type] => utility [patent_app_number] => 17/310459 [patent_app_country] => US [patent_app_date] => 2020-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28991 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -72 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17310459 [rel_patent_id] =>[rel_patent_doc_number] =>)